I am really looking forward to seeing more results from this trial. Something SI said has me intrigued:
"the companies are working closely together to complete analysis of a variety of secondary endpoints, including days in intensive care, other end-organ damage (potentially recovery), and measurement of circulating cytokines and biomarkers."
I added the parentheses; didn't include them in the transcript. But the way SI said this makes me think they belong there - that he was telling us we might see some recovery of "other end organ damage" following treatment with Remestemcel-L.
GLTAH!
Ann: COVID ARDS Trial Topline 60-Day Results, page-1389
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
0.100(4.13%) |
Mkt cap ! $3.025B | |||
| Open | High | Low | Value | Volume |
| $2.41 | $2.67 | $2.41 | $31.80M | 12.40M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 27487 | $2.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 32791 | 18 |
View Market Depth
| Last trade - 15.58pm 23/12/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
